Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improve survival in EGFR-mutant non-small cell lung cancer (NSCLC).
• Acquired resistance to EGFR TKIs remains a significant clinical challenge, limiting curative potential.
• Combination therapies are crucial for overcoming resistance and delaying disease progression in NSCLC.

Purpose of the Study:

• To investigate the efficacy of combined inhibition of polo-like kinase 1 (PLK1) and EGFR in TKI-sensitive EGFR-mutant NSCLC cells.
• To elucidate the molecular mechanisms underlying the combined inhibition of PLK1 and EGFR.
• To explore the potential of targeting PLK1 and EGFR concurrently for improved NSCLC treatment.

Main Methods:

• Pharmacological inhibition of PLK1 in TKI-sensitive EGFR-mutant NSCLC cell lines.
• Assessment of EGFR levels and Osimertinib sensitivity.
• Analysis of apoptosis induction.
• Investigation of the interaction between PLK1, EGFR, and c-Cbl.

Main Results:

• PLK1 inhibition destabilized EGFR protein levels in NSCLC cells.
• Combined PLK1 and EGFR inhibition sensitized cells to Osimertinib, inducing apoptosis.
• PLK1 was identified as a direct phosphorylation target of c-Cbl, a key EGFR ubiquitin ligase.
• PLK1 kinase activity influenced c-Cbl stability.

Conclusions:

• A novel interaction between mutant EGFR and PLK1 was identified in NSCLC.
• Co-targeting PLK1 and EGFR demonstrates potential to overcome resistance to EGFR TKIs.
• This combination strategy may enhance and prolong clinical responses in EGFR-mutated NSCLC patients.